Venture Funding Deals: New Cash For Delinia, Peloton, Fortis & Others
Executive Summary
Moderna and Intarcia lead recent fundraisings; big pharma backing includes Novartis leading Series A for Inflazome and Pfizer for diabetes play Antolrx. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced August through September 2016.
You may also be interested in...
Finance Watch: Q1 Biopharma Venture Capital Dips From All-Time High, But Numbers Still Impress
Private Company Edition: Biotech companies raised $3.9bn, down from $4.6bn in the first quarter of 2019 – a record-breaking year in the US – but dollars per deal stayed above $20m for a second year. Also, Fusion has April's second $100m-plus VC financing with a $105m Series B.
Finance Watch: Morphic's 'Smooth' Progress With Oral Integrin Inhibitors Justifies $80m Series B
Private Company Edition: Morphic raises $80m to take its first two integrin inhibitors into the clinic for fibrosis and inflammatory bowel disease. Also, Hillhouse has a new $10.6bn private equity fund for health care and other investments, and Atreca closes a $125m Series C.
Arix To Nurture Next Generation Biotechs After UK IPO
The supply of "permanent" capital and the desire to be involved operationally in new life science companies are some of the aims of Arix Bioscience, a UK company aiming to float on the London Stock Exchange, possibly by the end of this month.